89 related articles for article (PubMed ID: 21114460)
1. Dyslipidemia is a strong predictor of myocardial infarction in subjects with chronic kidney disease.
Holzmann MJ; Jungner I; Walldius G; Ivert T; Nordqvist T; Ostergren J; Hammar N
Ann Med; 2012 May; 44(3):262-70. PubMed ID: 21114460
[TBL] [Abstract][Full Text] [Related]
2. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study.
Tokmakova MP; Skali H; Kenchaiah S; Braunwald E; Rouleau JL; Packer M; Chertow GM; Moyé LA; Pfeffer MA; Solomon SD
Circulation; 2004 Dec; 110(24):3667-73. PubMed ID: 15569840
[TBL] [Abstract][Full Text] [Related]
3. LDL-C/apoB and HDL-C/apoA-1 ratios predict incident chronic kidney disease in a large apparently healthy cohort.
Bae JC; Han JM; Kwon S; Jee JH; Yu TY; Lee MK; Kim JH
Atherosclerosis; 2016 Aug; 251():170-176. PubMed ID: 27341533
[TBL] [Abstract][Full Text] [Related]
4. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction.
Stampfer MJ; Sacks FM; Salvini S; Willett WC; Hennekens CH
N Engl J Med; 1991 Aug; 325(6):373-81. PubMed ID: 2062328
[TBL] [Abstract][Full Text] [Related]
5. Impact of the apolipoprotein B/apolipoprotein A-I ratio on renal outcome in immunoglobulin A nephropathy.
Lundberg S; Gunnarsson I; Jacobson SH
Scand J Urol Nephrol; 2012 Apr; 46(2):148-55. PubMed ID: 22214235
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme gene polymorphism, lipids, and apolipoproteins in menopausal women on hormone replacement therapy.
Cubrilo-Turek M; Sertić J; Duraković Z
Acta Med Croatica; 2001; 55(4-5):161-7. PubMed ID: 12398019
[TBL] [Abstract][Full Text] [Related]
7. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men.
Lind L; Vessby B; Sundström J
Arterioscler Thromb Vasc Biol; 2006 Feb; 26(2):406-10. PubMed ID: 16306426
[TBL] [Abstract][Full Text] [Related]
8. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease.
Sniderman AD; Jungner I; Holme I; Aastveit A; Walldius G
J Intern Med; 2006 May; 259(5):455-61. PubMed ID: 16629851
[TBL] [Abstract][Full Text] [Related]
9. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
[TBL] [Abstract][Full Text] [Related]
10. The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years.
Rashidi A; Sehgal AR; Rahman M; O'Connor AS
Am J Cardiol; 2008 Dec; 102(12):1668-73. PubMed ID: 19064021
[TBL] [Abstract][Full Text] [Related]
11. Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study.
Brugts JJ; Knetsch AM; Mattace-Raso FU; Hofman A; Witteman JC
Arch Intern Med; 2005 Dec 12-26; 165(22):2659-65. PubMed ID: 16344425
[TBL] [Abstract][Full Text] [Related]
12. Impact of chronic kidney disease on postinfarction inflammation, oxidative stress, and left ventricular remodeling.
Naito K; Anzai T; Yoshikawa T; Anzai A; Kaneko H; Kohno T; Takahashi T; Kawamura A; Ogawa S
J Card Fail; 2008 Dec; 14(10):831-8. PubMed ID: 19041046
[TBL] [Abstract][Full Text] [Related]
13. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study.
Walldius G; Aastveit AH; Jungner I
J Intern Med; 2006 Mar; 259(3):259-66. PubMed ID: 16476103
[TBL] [Abstract][Full Text] [Related]
14. Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS).
Holme I; Aastveit AH; Jungner I; Walldius G
J Intern Med; 2008 Jul; 264(1):30-8. PubMed ID: 18298486
[TBL] [Abstract][Full Text] [Related]
15. Higher HDL cholesterol levels are associated with a lower incidence of chronic kidney disease in patients with type 2 diabetes.
Zoppini G; Targher G; Chonchol M; Perrone F; Lippi G; Muggeo M
Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):580-6. PubMed ID: 19196499
[TBL] [Abstract][Full Text] [Related]
16. Chronic kidney disease, lipids and apolipoproteins, and coronary heart disease: the ARIC study.
Lamprea-Montealegre JA; Sharrett AR; Matsushita K; Selvin E; Szklo M; Astor BC
Atherosclerosis; 2014 May; 234(1):42-6. PubMed ID: 24607852
[TBL] [Abstract][Full Text] [Related]
17. Beta-blockers for coronary heart disease in chronic kidney disease.
Chonchol M; Benderly M; Goldbourt U
Nephrol Dial Transplant; 2008 Jul; 23(7):2274-9. PubMed ID: 18187497
[TBL] [Abstract][Full Text] [Related]
18. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure.
Attman PO; Alaupovic P; Tavella M; Knight-Gibson C
Nephrol Dial Transplant; 1996 Jan; 11(1):63-9. PubMed ID: 8649654
[TBL] [Abstract][Full Text] [Related]
19. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality.
McCullough PA; Li S; Jurkovitz CT; Stevens L; Collins AJ; Chen SC; Norris KC; McFarlane S; Johnson B; Shlipak MG; Obialo CI; Brown WW; Vassalotti J; Whaley-Connell AT; Brenner RM; Bakris GL;
Am Heart J; 2008 Aug; 156(2):277-83. PubMed ID: 18657657
[TBL] [Abstract][Full Text] [Related]
20. Non-HDL-cholesterol to HDL-cholesterol ratio as an independent risk factor for the development of chronic kidney disease.
Zuo PY; Chen XL; Liu YW; Zhang R; He XX; Liu CY
Nutr Metab Cardiovasc Dis; 2015 Jun; 25(6):582-7. PubMed ID: 25921842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
